Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

Completed · Phase 2 · Has a placebo group

Conditions studied: Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy

In brief

This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult patients with narcolepsy. The study will enroll approximately 60 patients and eligible patients will be treated to receive either NLS-2 or placebo for 4-weeks.

Key facts

Study ID
NCT04923594
Run by
NLS Pharmaceutics
People needed
67
Starts
2021-09-13
Expected to finish
2022-06-30
Last updated by the study team
2022-08-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.